![]() |
|
![]() |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Venor®Mp & Venor®Mp - PCR Detection KitsKIT FOR IN VITRO DIAGNOSIS OF MYCOPLASMA PNEUMONIAE
The Venor®Mp system is an in vitro test for the qualitative and quantitative diagnosis of Mycoplasma pneumoniae in clinical samples. The test is based on the polymerase chain reaction, and thus providing highly sensitive and 100% specific rapid diagnosis. Venor®Mp is CE marked and approved for in vitro clinical diagnostics. The test system has undergone extensive internal validation, as well as external clinical evaluations. Venor®Mp is available as a conventional PCR
assay with result evaluation by agarose gel, as well as a quantitative
PCR probe system for use on all real-time instruments (Venor®Mp
Type 1 & Type 2). Ordering
Instrument Compatibility
+ = recommended kit version |
![]() Download
Instand CertificatesCertificate of AnalysisYou will find Your CoA of Your specific lot ins the menu below. [Download available as PDF-file]. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Benefits of Venor®Mp
Test PrincipleThe Venor®Mp Mycoplasma pneumoniae diagnostic kit uses specific primers to amplify a 207 bp nucleotide sequence within the highly conserved and multiple copy P1 cytadhesin gene. Various standard DNA preparation methods can be used for extraction of microbial DNA from respiratory samples followed by Venor®Mp PCR amplification. The amplicon is detected by standard agarose gel electrophoresis. To rule out the presence of PCR inhibitors in the patient specimen, an internal control is included in the kit. When there is no target DNA in the sample, a positive result from the internal control demonstrates that the PCR worked.
Quantitative and qualitative PCR assays:
We deploy Venor®Mp for the qualitative conventional
PCR or Venor®Mp Type 1 & Type 2 for the quantitative
qPCR. BackgroundMycoplasma pneumoniae is a continual source of upper respiratory
infections throughout the year and accounts for about 20% of community
acquired pneumonias. The spread increases within closed populations to
80%. The incidence of infection is greatest in older children, adolescents,
and young adults. The initial presenting symptoms of M. pneumoniae
infection after a 2-3 week incubation period may include cough,
fever, malaise, chills, sore throat, and headache. Asymptomatic infections
account for about 20% of cases. Mycoplasma pneumoniae infections
tend to be more chronic and indistingishable from viral causes and other
atypical pathogens on the basis of clinical symptoms alone. Thus, in many
clinical settings, accurate and rapid diagnosis is important for an efficient
patient management. Diagnosis of acute infections is usually based on
culture and serology, known to be difficult by means of insensitivity,
delayed detection, and poor specificity. Venor®Mp
Mycoplasma pneumoniae diagnostic kit incorporates the highly-sensitive
PCR technology and overcomes all drawbacks of these other techniques with
its unique features. Kit Components
We highly recommend our reliable hot-start MB Taq DNA Polymerase for extreme sensitive PCR detection of mycoplasma (Cat. No. 53-0200).
Venor®Mp kit components are lyophilized
and at +2 to +8 °C maintainable for at least 12 months. Primer and
nucleotides are aliquoted (á 25 tests) to guarantee consistent
quality. After rehydratisation the reagents must be stored at -18 °C. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| top |
| Update: 09.09.2010 // Contact // International Distributors // Terms and Conditions // Site Map // © 2010 Minerva Biolabs GmbH | |